The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes.
Silverman
Lewis R
LR
Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA. lewis.silverman@mssm.edu
D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077209:Decitabine; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D000077209:Decitabine; D008780:Methyltransferases; D001374:Azacitidine